Does Rallies show 13F holders for AMPH?

Yes. Rallies tracks hedge fund and 13F ownership data for AMPH, including fund names, share counts, latest tracked quarter, and position changes when available.

Is AMPH research on Rallies investment advice?

No. Rallies provides research, data, and educational context for AMPH. It does not provide personalized investment advice.

AMPH (Amphastar Pharmaceuticals, Inc.) Stock Analysis - Hedge Fund Holdings

Amphastar Pharmaceuticals, Inc. (AMPH) is a publicly traded Healthcare sector company. As of May 21, 2026, AMPH trades at $18.08 with a market cap of $758.40M and a P/E ratio of 10.47. AMPH moved +1.35% today. Year to date, AMPH is -32.34%; over the trailing twelve months it is -27.88%. Its 52-week range spans $16.65 to $53.96. Analyst consensus is neutral with an average price target of $22.00. Rallies surfaces AMPH's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.

Who owns AMPH stock?

Hedge funds tracked by Rallies that own AMPH include Exoduspoint Capital. The latest tracked quarter is Dec 31, 2025. Rallies shows current holdings, share counts, position changes, and 13F ownership context for Amphastar Pharmaceuticals, Inc..

AMPH Key Metrics

Key financial metrics for AMPH
Metric	Value
Price	$18.08
Market Cap	$758.40M
P/E Ratio	10.47
EPS	$1.71
Dividend Yield	0.00%
52-Week High	$53.96
52-Week Low	$16.65
Volume	0
Avg Volume	0
Revenue (TTM)	$720.53M
Net Income	$79.23M
Gross Margin	47.34%

Top Hedge Funds Holding AMPH

Exoduspoint Capital holds 14.93K shares of AMPH, changed -53.99% as of Dec 31, 2025.

Latest AMPH News

Amphastar Q1 EPS Drops to $0.42, Misses Consensus by $0.28 — May 7, 2026
Amphastar Sees Price Target Cut to $30, FDA Grants 180-Day Exclusivity — Mar 2, 2026
Amphastar Q4 Revenue Drops 1.8%, EPS Miss Leads to 15.8% Plunge — Feb 27, 2026
Amphastar Q4 Revenue Falls 2% as G&A Costs Surge 27% — Feb 27, 2026
Amphastar's 2025 Revenues Fall 2% on 45% Glucagon Drop, BAQSIMI Up 12% — Feb 27, 2026

Recent AMPH Insider Trades

Zhou Rong sold 9.79K (~$256.38K) on Dec 17, 2025.
Petersen Floyd F. sold 2.43K (~$62.89K) on Dec 12, 2025.
Petersen Floyd F. sold 1.74K (~$44.62K) on Dec 11, 2025.

AMPH Analyst Consensus

6 analysts cover AMPH: 0 strong buy, 0 buy, 6 hold, 0 sell, 0 strong sell. Consensus rating is neutral. Average price target: $22.00.

Common questions about AMPH

Who owns AMPH stock?: Hedge funds tracked by Rallies that own AMPH include Exoduspoint Capital. The latest tracked quarter is Dec 31, 2025. Rallies shows current holdings, share counts, position changes, and 13F ownership context for Amphastar Pharmaceuticals, Inc..
Does Rallies show 13F holders for AMPH?: Yes. Rallies tracks hedge fund and 13F ownership data for AMPH, including fund names, share counts, latest tracked quarter, and position changes when available.
Is AMPH research on Rallies investment advice?: No. Rallies provides research, data, and educational context for AMPH. It does not provide personalized investment advice.